ArticleFrontiers in nutrition2026
Association and predictive value of sarcopenic obesity for the prognosis of lung cancer patients receiving immune checkpoint inhibitors.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between handgrip strength and visceral obesity with low appendicular skeletal muscle mass in Chinese adults.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenic obesity (SO) has been established as a reliable predictor of prognosis for several cancer types; however, its role in the prognosis of lung cancer patients receiving immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to explore the potential predictive value of SO on survival outcomes in lung cancer patients undergoing ICI therapy. Methods: From May 2018 to October 2020, lung cancer patients who received immunotherapy at a tertiary hospital in Henan Province were retrospectively evaluated using data from the electronic medical record system. Data on demographic characteristics, biochemical markers, current illnesses and treatments, and nutrition-related information were documented. Sarcopenia was evaluated using the skeletal muscle index (SMI) (cm Results: The 119 participants were divided into four groups: control, sarcopenia, obesity, and SO. Among these participants, 15.13% were diagnosed with SO. The results demonstrated that for 3-year survival rates, patients with SO had the highest mortality rate (with a median survival of 22.55 months), followed by those with sarcopenia alone (median survival: 28.29 months) and those with obesity alone (median survival: 28.99 months) ( Conclusion: SO is an independent prognostic factor for lung cancer patients receiving immunotherapy. Early identification and targeted management of sarcopenic obesity are crucial for optimizing treatment strategies and improving survival outcomes in ICI-treated lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.